[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5663205" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-04-02" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://www.reactome.org/biopax/63/48887#Pathway1589> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://www.reactome.org/biopax/63/48887#Pathway1675>
] .

<http://www.reactome.org/biopax/63/48887#Pathway1589>
        a       <http://www.biopax.org/release/biopax-level3.owl#Pathway> , <http://purl.obolibrary.org/obo/GO_0008150> , <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "Infectious diseases are ones due to the presence of pathogenic microbial agents in human host cells. Processes annotated in this category include the life cycles of influenza virus and HIV (human immunodeficiency virus), some metabolic processes mediated by intracellular Mycobacterium tuberculosis, the actions of clostridial, anthrax, and diphtheria toxins, and the entry of Listeria monocytogenes into human cells." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Infectious disease" ;
        <http://geneontology.org/lego/hint/layout/x>
                2450 ;
        <http://geneontology.org/lego/hint/layout/y>
                50 ;
        <http://purl.obolibrary.org/obo/BFO_0000050>
                <http://www.reactome.org/biopax/63/48887#Pathway1259> ;
        <http://purl.obolibrary.org/obo/BFO_0000051>
                <http://www.reactome.org/biopax/63/48887#Pathway1675> , <http://www.reactome.org/biopax/63/48887#Pathway1669> , <http://www.reactome.org/biopax/63/48887#Pathway1590> , <http://www.reactome.org/biopax/63/48887#Pathway1640> , <http://www.reactome.org/biopax/63/48887#Pathway1688> ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5663205" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/BFO_0000051>
        a       <http://www.w3.org/2002/07/owl#ObjectProperty> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has part" .

<http://purl.obolibrary.org/obo/RO_0002327>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "enables" .

<http://purl.org/pav/providedBy>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/CHEBI_36080>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "chebi protein" .

<http://purl.obolibrary.org/obo/RO_0002406>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly activates (process to process)" .

<http://www.reactome.org/biopax/63/48887#Pathway1675>
        a       <http://www.biopax.org/release/biopax-level3.owl#Pathway> , <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/GO_0008150> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "The toxic effects of many bacteria on their human hosts are mediated by proteins released from the bacteria that enter human cells and disrupt critical cellular functions (Henkel et al. 2010). All of the ones annotated here share a bipartiite mechanism of host intoxication: one moiety binds target cells and mediates the delivery of the other part to the intracellular compartment where it can function as an enzyme to degrade or derivatize and inactivate critical target cell proteins or to activate constitutive synthesis of high levels of cAMP." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Uptake and actions of bacterial toxins" ;
        <http://geneontology.org/lego/hint/layout/x>
                3100 , 2450 ;
        <http://geneontology.org/lego/hint/layout/y>
                1400 , 50 ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5663205" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://www.reactome.org/biopax/63/48887#Pathway1590>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/GO_0016032> , <http://www.biopax.org/release/biopax-level3.owl#Pathway> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "The global pandemic of Human Immunodeficiency Virus (HIV) infection has resulted in tens of millions of people infected by the virus and millions more affected. UNAIDS estimates around 40 million HIV/AIDS patients worldwide with 75% of them living in sub-Saharan Africa. The primary method of HIV infection is by sexual exposure while nonsexual HIV transmission also can occur through transfusion with contaminated blood products, injection drug use, occupational exposure,accidental needlesticks or mother-to-child transmission. HIV damages the immune system, leaving the infected person vulnerable to a variety of \"opportunistic\" infections arising from host immune impairment (Hare, 2004).<br>HIV-1 and the less common HIV-2 belong to the family of retroviruses. HIV-1 contains a single-stranded RNA genome that is 9 kilobases in length and contains 9 genes that encode 15 different proteins. These proteins are classified as: structural proteins (Gag, Pol, and Env), regulatory proteins (Tat and Rev), and accessory proteins (Vpu, Vpr, Vif, and Nef) (Frankel and Young,1998).<br><b>HIV infection </b>cycle can be divided into two phases:<br>1. An <b>Early phase</b> consisting of early events occuring after HIV infection of a susceptible target cell and a <br>2. <b>Late phase</b> comprising the later events in the HIV-infected cell resulting in the assembly of new infectious virions. The section titled <b>HIV lifecycle</b> consists of annotations of events in these two phases.<br>The virus has developed various molecular strategies to suppress the antiviral immune responses (innate, cellular and humoral) of the host. HIV-1 viral auxiliary proteins (Tat, Rev, Nef, Vif, Vpr and Vpu) play important roles in these host-pathogen interactions (Li et al.,2005). The section titled <b>Host interactions of HIV factors</b> will highlight these complex post-infection processes and the annotations will be released in near future.<br>" ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "HIV Infection" ;
        <http://geneontology.org/lego/hint/layout/x>
                4400 , 2450 ;
        <http://geneontology.org/lego/hint/layout/y>
                2300 , 50 ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5663205" , "Authored: Bukrinsky, Michael, D'Eustachio, Peter, Gillespie, Marc E, Gopinathrao, G, Iordanskiy, S, Morrow, MP, Matthews, Lisa, Rice, AP" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/BFO_0000002>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Continuant" .

<http://purl.obolibrary.org/obo/GO_0008150>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Biological Process" .

<http://www.reactome.org/biopax/63/48887#Pathway1688>
        a       <http://www.biopax.org/release/biopax-level3.owl#Pathway> , <http://purl.obolibrary.org/obo/GO_0035635> , <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "Listeria monocytogenes is a short, gram-positive, nonspore-forming motile rod. Serotypes 1/2a, 1/2b and 4b make up more than 95% of isolates from humans, with serotype 4b causing most of the food-borne outbreaks. Listeria monocytogenes enters the body through the gastrointestinal tract after ingestion of contaminated food. The bacteria can survive food preservation procedures, such as refrigeration, low pH and high salt.<br>Listeria monocytogenes expresses several adhesin proteins at the cell surface that facilitate bacterial binding and entry to host cells. The bacteria can enter host cells through endocytosis mediated by binding of the bacterial InlA (internalin) protein to CDH1 (E-cadherin) at the host cell plasma membrane. Listeria monocytogenes can also enter host cells through endocytosis mediated by binding of the bacterial InlB protein to MET receptor tyrosine kinase at the host cell plasma membrane. Listeria monocytogenes proliferates inside the host cells and triggers formation of filopods, elongated protrusions of the host plasma membrane that contain bacteria. Filopods are ingested by adjacent cells, allowing Listeria monocytogenes to spread from cell to cell, invisible to the immune system of the host.<br>Listeria monocytogenes can cross the intestinal, blood-brain and placental barriers. In immunocompetent adults Listeria monocytogenes infection usually causes gastroenteritis. In infants infected in utero and in immunocompromised adults Listeria monocytogenes infection can result in meningoencephalitis and bacteremia (sepsis).<br>InlA is critical for crossing the intestinal barrier while both InlA and InlB are needed for crossing the placental barrier (Gessain et al. 2015) and, based on in vitro studies, the blood-cerebrospinal fluid barrier (Grundler et al. 2013). It seems that the intrinsic level of PI3K activity in Listeria-targeted host cells determines whether the entry depends on InlA only or InlA and InlB. The interaction of InlA with E-cadherin does not activate PI3K/AKT signaling while the interaction of InlB with the MET receptor activated the PI3K/AKT signal transduction cascade. Therefore, InlB-MET interaction may be important in tissues with low intrinsic PI3K activity (Gessain et al. 2015). Even if InlA-E-cadherin route is sufficient for bacterial entry, InlB may accelerate bacterial invasion (Pentecost et al. 2010). Cholesterol levels in host cell plasma membrane may also influence the preferred route for bacterial endocytosis (Seveau et al. 2004). In addition to InlA and InlB, many other virulence factors are involved in the Listeria monocytogenes infection cycle (Camejo et al. 2011) and will be annotated as mechanistic details become available.<br>For review, please refer to Bonazzi et al. 2009, Brooks et al. 2010, Camejo et al. 2011, Pizarro-Cerda et al. 2012." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Listeria monocytogenes entry into host cells" ;
        <http://geneontology.org/lego/hint/layout/x>
                1800 ;
        <http://geneontology.org/lego/hint/layout/y>
                50 ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Authored: Orlic-Milacic, Marija, 2016-06-14" , "https://reactome.org/content/detail/R-HSA-5663205" , "Reviewed: Schwerk, Christian, 2016-10-25" , "Edited: Orlic-Milacic, Marija, 2016-10-26" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002334>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "regulated by" .

<http://purl.obolibrary.org/obo/BFO_0000015>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Process" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5663205" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-04-02" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://www.reactome.org/biopax/63/48887#Pathway1589> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://www.reactome.org/biopax/63/48887#Pathway1669>
] .

<http://purl.obolibrary.org/obo/RO_0002234>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has output" .

<http://purl.obolibrary.org/obo/RO_0002413>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly provides input for (process to process)" .

<http://purl.obolibrary.org/obo/BFO_0000050>
        a       <http://www.w3.org/2002/07/owl#ObjectProperty> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "part of" .

<http://purl.obolibrary.org/obo/GO_0032991>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Macromolecular Complex" ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/BFO_0000002> .

<http://purl.obolibrary.org/obo/GO_0035635>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/GO_0008150> .

<http://purl.obolibrary.org/obo/RO_0002333>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "enabled by" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5663205" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-04-02" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://www.reactome.org/biopax/63/48887#Pathway1589> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://www.reactome.org/biopax/63/48887#Pathway1640>
] .

<http://purl.obolibrary.org/obo/RO_0002233>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has input" .

<http://www.reactome.org/biopax/63/48887#Pathway1640>
        a       <http://www.biopax.org/release/biopax-level3.owl#Pathway> , <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/GO_0019058> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "For centuries influenza epidemics have plagued man, and influenza was probably the disease described by Hippocrates in 412 BC. Today it remains a major cause of morbidity and mortality worldwide with large segments of the human population affected every year. Many animal species can be infected by influenza viruses, often with catastrophic consequences. A continuing threat is the possibility of a pandemic similar to that experienced in 1918, estimated to have been responsible for 50 million deaths worldwide.<p>Influenza viruses belong to the family of Orthomyxoviridae; viruses with segmented RNA genomes that are negative sense and single-stranded (Baltimore 1971).<p>Influenza virus strains are named according to their type (A, B, or C), the species from which the virus was isolated (omitted if human), location of isolate, the number of the isolate, the year of isolation, and in the case of influenza A viruses, the hemagglutinin (H) and neuraminidase (N) subtype. For example, the virus of H5N1 subtype isolated from chickens in Hong Kong in 1997 is: influenza A/chicken/Hong Kong/220/97(H5N1) virus. Currently 16 different hemagglutinin (H1 to H16) subtypes and 9 different neuraminidase (N1 to N9) subtypes are known for influenza A viruses. Most human disease is due to Influenza viruses of the A type, so the events of Influenza infection have been annotated in Reactome with reference to this type." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Influenza Infection" ;
        <http://geneontology.org/lego/hint/layout/x>
                2450 , 3750 ;
        <http://geneontology.org/lego/hint/layout/y>
                1850 , 50 ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Reviewed: Garcia-Sastre, A, Squires, B, 2006-10-30 21:55:36" , "Authored: Luo, F, Squires, B, Scheuermann, RH, 2006-01-05 15:13:12" , "https://reactome.org/content/detail/R-HSA-5663205" , "Edited: D'Eustachio, P, Gillespie, ME, 2006-01-07 21:50:17" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://geneontology.org/lego/hint/layout/y>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://www.reactome.org/biopax/63/48887#Pathway1259>
        a       <http://purl.obolibrary.org/obo/GO_0008150> , <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://www.biopax.org/release/biopax-level3.owl#Pathway> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "Biological processes are captured in Reactome by identifying the molecules (DNA, RNA, protein, small molecules) involved in them and describing the details of their interactions. From this molecular viewpoint, human disease pathways have three mechanistic causes: the inclusion of microbially-expressed proteins, altered functions of human proteins, or changed expression levels of otherwise functionally normal human proteins.<p>The first group encompasses the infectious diseases such as influenza, tuberculosis and HIV infection. The second group involves human proteins modified either by a mutation or by an abnormal post-translational event that produces an aberrant protein with a novel function. Examples include somatic mutations of EGFR and FGFR (epidermal and fibroblast growth factor receptor) genes, which encode constitutively active receptors that signal even in the absence of their ligands, or the somatic mutation of IDH1 (isocitrate dehydrogenase 1) that leads to an enzyme active on 2-oxoglutarate rather than isocitrate, or the abnormal protein aggregations of amyloidosis which lead to diseases such as Alzheimer's.<p>Infectious diseases are represented in Reactome as microbial-human protein interactions and the consequent events. The existence of variant proteins and their association with disease-specific biological processes is represented by inclusion of the modified protein in a new or variant reaction, an extension to the 'normal' pathway. Diseases which result from proteins performing their normal functions but at abnormal rates can also be captured, though less directly. Many mutant alleles encode proteins that retain their normal functions but have abnormal stabilities or catalytic efficiencies, leading to normal reactions that proceed to abnormal extents. The phenotypes of such diseases can be revealed when pathway annotations are combined with expression or rate data from other sources." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Disease" ;
        <http://geneontology.org/lego/hint/layout/x>
                1150 ;
        <http://geneontology.org/lego/hint/layout/y>
                50 ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5663205" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/GO_0019058>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/GO_0008150> .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5663205" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-04-02" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://www.reactome.org/biopax/63/48887#Pathway1589> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://www.reactome.org/biopax/63/48887#Pathway1590>
] .

<http://geneontology.org/lego/hint/layout/x>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://www.biopax.org/release/biopax-level3.owl#Pathway>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Pathway" ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/BFO_0000015> .

<http://purl.org/dc/elements/1.1/date>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://geneontology.org/lego/modelstate>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/CHEBI_33695>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "chebi gene" .

<http://purl.obolibrary.org/obo/RO_0001025>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "located in" .

<http://model.geneontology.org/239011869>
        a       <http://www.w3.org/2002/07/owl#Ontology> ;
        <http://geneontology.org/lego/modelstate>
                "development" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5663205" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/dc/elements/1.1/title>
                "Reactome::Infectious disease" .

<http://purl.obolibrary.org/obo/GO_0003674>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Molecular Function" .

<http://purl.obolibrary.org/obo/RO_0002429>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "involved in positive regulation_of" .

<http://purl.obolibrary.org/obo/GO_0051701>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/GO_0008150> .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5663205" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-04-02" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000050> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://www.reactome.org/biopax/63/48887#Pathway1589> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://www.reactome.org/biopax/63/48887#Pathway1259>
] .

<http://purl.obolibrary.org/obo/RO_0002024>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly positively regulated by" .

<http://purl.obolibrary.org/obo/BFO_0000066>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "occurs in" .

<http://www.biopax.org/release/biopax-level3.owl#Reaction>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Reaction" ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/BFO_0000015> .

<http://purl.org/dc/elements/1.1/contributor>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/RO_0002408>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly inhibits (process to process)" .

<http://purl.obolibrary.org/obo/GO_0016032>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/GO_0008150> .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5663205" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-04-02" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://www.reactome.org/biopax/63/48887#Pathway1589> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://www.reactome.org/biopax/63/48887#Pathway1688>
] .

<http://purl.obolibrary.org/obo/RO_0002430>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "involved in negative regulation_of" .

<http://www.biopax.org/release/biopax-level3.owl#Protein>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Protein" ;
        <http://www.w3.org/2000/01/rdf-schema#subClassOf>
                <http://purl.obolibrary.org/obo/BFO_0000002> .

<http://purl.org/dc/elements/1.1/title>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/RO_0002428>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "involved in regulation of" .

<http://www.reactome.org/biopax/63/48887#Pathway1669>
        a       <http://purl.obolibrary.org/obo/GO_0051701> , <http://www.biopax.org/release/biopax-level3.owl#Pathway> , <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "Infection by <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) is soon countered by the host's immune system, the organism is however almost never eradicated; ten per cent of infections will develop into \"open tuberculosis\", while the other ninety per cent become \"latent\", a state that can persist for decades until loss of immune control. A third of the world's population is estimated to harbour latent tuberculosis. Latent infection involves the bacterium being internalized by macrophages where it stops and counters the innate immune answer (Russell 2011, Russell et al. 2010). When a status-quo is reached, <i>Mtb</i> enters a non-replicating persistent state (Barry et al. 2009, Boshoff & Barry 2005)." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Latent infection of Homo sapiens with Mycobacterium tuberculosis" ;
        <http://geneontology.org/lego/hint/layout/x>
                500 ;
        <http://geneontology.org/lego/hint/layout/y>
                50 ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Reviewed: Warner, D, 2012-04-30" , "Edited: Jassal, B, 2011-02-28" , "https://reactome.org/content/detail/R-HSA-5663205" , "Authored: Stephan, R, 2011-01-10" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-04-02" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002023>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly negatively regulated by" .
